Concepedia

A Howe

AH

20

Publications

1.1K

Citations

16

H-Index

1992

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Carmel Medical Center

University of British Columbia

The University of Texas Health Science Center at San Antonio

Rambam Health Care Campus

A Howe is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in hepatitis, medicine, and viral hepatitis.

ORCID

Top concepts

Publications per year

1992–2022

20

Publications

20

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

Eric Lawitz, Edward Gane, Brian L. Pearlman et al. · The Lancet · 2014 · 299 citations

, , +10

Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent

Xavier Forns, Stuart C. Gordon, Eli Zuckerman et al. · Journal of Hepatology · 2015 · 140 citations

, , +7

Kinetic Analyses Reveal Potent and Early Blockade of Hepatitis C Virus Assembly by NS5A Inhibitors

David R. McGivern, Takahiro Masaki, Sara E. Williford et al. · Gastroenterology · 2014 · 107 citations · Full text

, , +10

Susceptibilities of Genotype 1a, 1b, and 3 Hepatitis C Virus Variants to the NS5A Inhibitor Elbasvir

Rong Liu, Stephanie Curry, Patricia McMonagle et al. · Antimicrobial Agents and Chemotherapy · 2015 · 76 citations · Full text

A novel recombinant single‐chain hepatitis C virus ns3‐ns4a protein with improved helicase activity

A Howe, Robert A. Chase, S. Shane Taremi et al. · Protein Science · 1999 · 51 citations · Full text

, , +17

Rows per page

1–5 of 20